# Synaura

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synaura

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.synaura.cn
- Total disclosed funding: $14M
- Latest round: Series A (May 19, 2026)
- Investors on record: 4

## About

Based in Shanghai, China and founded in 2022, Synaura Biotechnology (Shanghai) Co., Ltd., trading as Synaura, is a biotech company that focuses on developing synthetic biology methods. As of 2024, the company has obtained an HMO production license and 2023 Emerging Biotech Enterprises Ranking and People's Craftsmanship and Technology Award certificates. In May 2026, Synaura raised a Series A funding from Changkejin Investment.

The company's main product is human milk oligosaccharides (HMOs). Breast milk oligosaccharides include neutral fucosylated HMOs, neutral non-fucosylated HMOs, and acidic sialylated HMOs. The company's products are used in infant formula food, adult nutrition products, and milk and dairy products.

The company’s revenue is generated by providing human milk oligosaccharides (HMOs).

The Series A funding raised in May 2026 will be primarily used for core technology iteration, capacity expansion, and market channel development, helping the company further solidify its independent R&D and industrialization advantages in human milk oligosaccharides (HMOs), accelerate the breaking of international monopolies, and promote the rise of domestic HMO raw materials.

## Funding rounds

- Series A, May 19, 2026 — Changkejin Investment
- Series B, Feb 6, 2026, $14M — Anhui Venture Investment, Hefei High-tech Venture Capital, Xinping Capital

## Investors

- Anhui Venture Investment — Series B
- Hefei High-tech Venture Capital (https://capitalatlas.ai/funds/hefei-high-tech-venture-capital) — Series B
- Xinping Capital — Series B
- Changkejin Investment (https://capitalatlas.ai/funds/changkejin-investment) — Series A